DHR Health Welcomes Dr. Fernando Lambreton Hinojosa, Specializing in Colon and Rectal Surgery

Translate to Spanish or other 102 languages!

DHR Health is pleased to announce its newest surgeon, Dr. Fernando Lambreton Hinojosa to its esteemed team at the DHR Health Surgery Institute. Images courtesy of DHR Health
DHR Health is pleased to announce its newest surgeon, Dr. Fernando Lambreton Hinojosa to its esteemed team at the DHR Health Surgery Institute. Images courtesy of DHR Health
- Advertisement -

EDINBURG, Texas – DHR Health is pleased to announce its newest surgeon, Dr. Fernando Lambreton Hinojosa to its esteemed team at the DHR Health Surgery Institute. Dr. Lambreton Hinojosa is fellowship trained, specializing in colon and rectal surgery. In his role, he will be diagnosing and treating conditions in this area, including anorectal diseases such as anal cancer, hemorrhoids, fistula, and prolapse. Additionally, he will specialize in minimally-invasive and robotic-assisted surgery procedures using the latest technology, only available at DHR Health. 

Originally from Monterrey, Mexico, Dr. Lambreton Hinojosa is fluent in English and Spanish. He earned his medical degree from University of Monterrey Medical School graduating with high honors in 2016. Upon graduation, he went on to complete his residency training in general surgery at the University of Texas Medical Branch in Galveston, Texas. He then furthered his medical education by completing a fellowship in colon and rectal surgery from Baylor University Medical Center. 

“It is with great pleasure to extend a warm welcome to Dr. Lambreton Hinojosa,” said Marissa Castaneda, Senior Executive Vice President of DHR Health. “His expertise and commitment to patient care aligns with our mission of providing the highest quality of health care.”

- Advertisement -

Dr. Lambreton Hinojosa is currently a member of the American College of Surgeons, American Society of Colon and Rectal Surgeons, and Latino Surgical Society. He has authored several publications and has proudly presented extensively in his field. 

“I am thrilled to join the medical community in the Rio Grande Valley and contribute to the health and well-being of its residents. As a colorectal surgeon, I look forward to using my skills and expertise to address the unique needs of our patients and make a positive impact on their lives,” he said.

Dr. Lambreton Hinojosa is accepting patient referrals and will see new patients at this office located at the DHR Health Medical Office Building located at 1100 E. Dove Avenue, Suite 300 in McAllen. Patients seeking surgical consultations should first consult with their primary care physician for a referral. For an appointment call (956) 362-8170. DHR Health accepts most medical insurances, including Medicare and Medicaid.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health Transplant Success Signals a New Era for Advanced Medicine in the Rio Grande Valley

The significance of DHR Health Transplant Institute’s latest recognition extends far beyond a hospital ranking. It raises a larger question for South Texas: Has the Rio Grande Valley reached the point where patients can look to the region not only for local healthcare, but for nationally competitive transplant medicine?

STHS Earns Another 5-Star Healthgrades Distinction for Hip Fracture Care

For the sixth consecutive year, STHS McAllen and STHS Edinburg have earned a Five-Star Rating for Hip Fracture Treatment from Healthgrades, one of the nation's leading resources for evaluating hospital performance.

Raising Awareness, One Step at a Time: STHS Edinburg Hosts Sept. 23 Walkathon

To raise awareness about the condition and encourage residents to take proactive steps toward better vascular health, the STHS Limb Salvage & Amputation Prevention Program will host the Step Out PAD Walkathon on Wednesday, September 23, 2026, at STHS Edinburg, from 6:30 to 7:30 p.m.

FDA Launches Expedited IND Pilot to Speed Up Clinical Trials

The U.S. Food and Drug Administration today announced the final design of the Expedited Investigational New Drug (IND) Pilot. Accelerating clinical trial timelines and eliminating regulatory hurdles to maintain American leadership in global medical innovation is a core priority for the Trump Administration.
- Advertisement -